Current Price @3.40 Found support @2.86 and 2.68 Long -Holding above @3.60 bullish , PT @3.81, @3.98 (hard resistance), and @4.90 above that. -Unless we gap over @4.01 and break over the daily resistance trend line we will most likely see CYDY get shorted to the ground. Most likely into the @2.1 to @1.5 gap fill range. Short -Leaning Bearish as the market...
CYDY finally published good statistical significance numbers for their mild/moderate COVID study but price has not reacted yet. The fractal micro count (italics) needed one more lower low to 4.2 to complete v of (5) of ii before wave iii of 3 can start. Or we could be in for more abcde of ii consolidation in 4-6.5 range. Either way should rally here.
CYDY has completed 5 micro waves down from i 6.8 area to ii 4.4 area. This should be launching point towards teens from next week's topline efficacy report for Phase II mild/moderate COVID trial. Nader has already hinted that statistically significant positive results will be presented for several meaningful secondary endpoints, if not the loosely defined...
After it's 10-day run to $10, CYDY did not hold expected support at $4.6. That turned out to be just A wave in ABC correction to $2.8 on unexpected FDA-imposed delay in HIV Combo BLA application. That was our most glaring miss in this series of CYDY projections. At least we see strong A=C proportionality suggesting the correction completed Monday the 13th:...
The CYDY consolidation we expected after the spike to $10 may have finished this morning with c wave to $4.75, despite break of $5. Or if trial news is further delayed the triangle could continue to elongate with additional legs (blue path) keeping a short-term bullish bias as long as last week's $4.6 (and $4.75) lows hold.
But this is a huge fractal growth structure now so it's attack on the teens is not at all done! We should see a triangle consolidation between $6-$9 followed by a trip to $12 minimum, with aftershocks taking it to $15-20 later this year. We kept taking profits on our trading portion up to $9.90 this morning then got a chance to buy back some we'd sold too early at $5-6.
Earlier in the week we said CYDY needed to turn parabolically upwards in a steeper channel for technicals to catch up with the rosy speculative fundamentals of high likelihood COVID approval in July. We got the slope of this new channel perfect but it started even quicker than projected. Here's an updated fractal projection that fills the gap at 6, goes straight...
This week CYDY has reached the mid-$4 range predicted in April to complete the fractal growth channel since late 2019 lows at $.26. Since April, we know Cytodyn has treated at least 80 COVID patients in its Phase II mild-moderate trial, 70 in its Phase III severe trial and at least 75 EIND emergency patients outside blind trials. We know from Dr. Bruce...
Using Tom Demark trend analysis, $3.58 target. Ideally, entry @$2.67 on a pullback. Stop loss at $2.36, reward/risk= 3:1 CYDY is on a tear up around 50% in the last week, breaking a short term trend, and confirming upside breakout.
Here's another possible fractal path for CYDY over coming weeks. It appears to be consolidating and basing in 2.76-3.2 zone ready for an attack on 3.57-3.65, then 3.83-4 and eventually the old 2011 all-time high around 4.4 (when there were WAY fewer outstanding shares!). This sort of stair-stepped march-up can be expected so long as trial results and partnering...
The super-hot bio-tech startup Cytodyn with their humanized monoclonal antibody Leronlamib has been on a tear up 1000% since November 2019 lows ($.26). The rally has been driven by many press releases: stabilized financing and marketing contracts, amazing results in their early cancer trials and now serendipitous immunological application to severe coronavirus...
Here's a closeup on the CYDY micro-fractal action this week. Notice the clear 5 wave structure in each triangle up-leg. Trimming at the top and buying back at the bottom of the triangle for a few days before wave V comes on what -- BLA submission news?
Cytodyn is a 9-year old biotech startup nearing FDA approval for Leronlamib, a humanized monoclonal antibody that's shown no side effects with over 800 AIDS patients through a Phase 3 HIV combo-therapy trial. But Leronlamib is also showing broad efficacy in early trials for HIV monotherapy, HIV prevention, blocking metastasis of many cancers, graft vs host...
development broke out huge last week with its cancer and HIV drug. With these companies, I think it is more news driven than chart driven.
RSI under 70, potential upside left. Enter a short position at 1.4180 or higher, cover at 1.1090 . You can trade the consolidation area highlighted by the yellow triangle, from 1.26-1.38 with very tight stops, as once the consolidation is broken, 1.090 is your next stop. Only high volume trades, min. 1k shares. (ps. If price fails to break...